New Surgical Technologies Featured at the Company’s Exhibit Booth
VAUGHAN, Ontario, August 28, 2024 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of new scientific data and educational events taking place during the European Society of Cataract and Refractive Surgery (ESCRS) annual meeting in Barcelona, Spain, September 6-10.
Scientific posters and papers will highlight the results of studies evaluating Bausch + Lomb Surgical technologies including TECHNOLAS TENEO™ 317 Model 2, novel premium IOLs such as the IC-8 Apthera™ intraocular lens (IOL) and the Minimally Invasive Nasal Trabeculostomy, or MINT™*, device. Sponsored educational events will focus on these and other Bausch + Lomb products.
At the Bausch + Lomb exhibit booth (Hall 7, D-35), the company will feature several additional new surgical offerings. These include the newly CE Marked OCTAVIUS™ Customized Corneal Treatment, a premium procedure performed on the TENEO Excimer Laser that utilizes the patient’s individual topography data to provide a customized corneal treatment approach, and ScoutPro®, a point-of-care portable device for precisely measuring osmolarity.
Bausch + Lomb activities at ESCRS:
Spotlight Abstract
- “Multicentric Clinical Study to Determine Safety and Efficacy of a new Hydrophobic Acrylic Full Range of Vision Intraocular Lens (IOL).”Cochener B.
Paper Presentations
- “A Case Series Evaluating the Early Efficacy and Safety Outcomes of Minimally Invasive Micro Sclerostomy (MIMS®) Using Direct Visualization in Patients with Glaucoma in the UK.” Dervenis P, Dimitriou C.
- “A Prospective, Multicenter, Randomized, US Clinical Trial Evaluating the Visual and Refractive Outcomes Following Bilateral Implantation of a Novel Full Visual Range Trifocal or Monofocal Intraocular Lens.”Shultz, M.
- “Assessment of the Binocular Defocus Curve and Contrast Sensitivity in Patients Implanted Bilaterally with a Novel Full Visual Range Trifocal or Monofocal Intraocular Lens: A US Prospective, Randomized, Controlled Study.”Chu R.
- “Laser-Assisted in Situ Keratomileusis Using a Novel Aspheric Ablation Algorithm for the Correction of Myopia and Myopic Astigmatism: Visual and Refractive Outcomes.” Stonecipher K.
- “Refractive Outcomes Following Implantation Of An Ultra-Low Cylinder Powered (0.90 D) Toric IOL In Eyes Predicted To Have Low Amounts Of Visually Significant Postoperative Astigmatism.” Muzychuk A.
- “Patient-Reported Visual Outcomes after Bilateral Implantation of a Novel Refractive Trifocal Intraocular Lens in Comparison to its Parent Monofocal Intraocular Lens.” Mendicute J, Garcia Bella J.
- “Subjective Evaluation of the Patient-Reported Outcomes and Contrast Sensitivity Following Laser in Situ Keratomileusis (LASIK) Performed Using a Novel Aspheric Ablation Profile for the Correction of Myopia and Myopic Astigmatism.” Chu R.
- “Visual and Refractive Outcomes and Quality of Vision Following Bilateral Implantation of a Novel Trifocal Intraocular Lens that Provides a Full Range of Vision in Cataract Patients: A Canadian Multicenter Study.”Harasymowycz P.
- “Visual Outcomes of a Novel Trifocal Intraocular Lens in Comparison to its Monofocal Equivalent Intraocular Lens.” Castro F.
- “Evaluation Of Visual Outcomes In Patients With Aberrated Corneas Implanted With The Ic-8 Small-Aperture Iol”. Teo Z.
Presented Posters
- “First Experience With Topography Guided Ablation Treatment Based on OCT Readings.” Nouira F.
- “One-Year Clinical Outcomes of Two Different Ablation Profiles (Regular And Strong) with the Supracor Presbyopic Lasik Treatment.” Ang RE.
- “Performance and Safety of Minimally Invasive Nasal Trabeculostomy (MINT™) in Open-Angle Glaucoma: a 12-Month Open-Label Study.” Voskanyan L.
- “Wavefront Analysis and Optical Performance of a Novel Aspheric Monofocal Intraocular Lens with a Higher Order Aspheric Coefficient Designed to Improve Depth of Focus.” Barros, M.
- “Spectacle Independence and Visual Outcomes After Bilateral Implantation of a Monofocal Plus IOL Compared to a Monofocal IOL: a Randomized Clinical Trial.” Pagnaco C, Pedrotti E.
- “Defocus Curve Performance and Near Activity Visual Questionnaire Outcomes Following Bilateral Implantation of a Novel Full Range of Vision Trifocal IOL among Cataract Patients.” Muzychuk, A.
Posters
- “Evaluation Of The Safety Of A Novel Preservative-Free Formulation Of Brimonidine Tartrate Ophthalmic Solution.” Miranda M et al.
- “Clinical Evaluation Of A Multi-Ingredient Oral Supplement On Dry Eye Symptoms And Tear Volume.” Diaz Valle D et al.
- “Performance and Safety of the Minimally Invasive Micro Sclerostomy (MIMS) Inferonasal Procedure in Patients with Medically Uncontrolled or Refractory Open-Angle Glaucoma: 52-Week Open-Label Study.” Voskanyan L.
- “A Single-Centre Case Series Evaluating the Safety and Efficacy of Minimally Invasive Micro Sclerostomy in Patients with Glaucoma and Ocular Hypertension in Germany.” Jünemann A, Rejdak R.
- “Clinical Outcomes of an Enhanced Depth of Focus Toric Intraocular Lens.” Noguera, H
- “Comparison of Subjective and Objective Depth of Focus Curve Using Ray-Tracing Aberrometry in Aberrated Corneas Implanted with a Small Aperture IOL.” Barros, M.
- “Physicians’ Experience and Initial Patient Outcomes with the Minimally Invasive Micro Sclerostomy (MIMS) Procedure for Open-Angle Glaucoma.” Shultz M.
- “Hyperosmolarity Causes Increased Variation Of Light Scatter Following Cataract Surgery”. Nijm, L.
Special Events
Saturday 7th September
Lunchtime Symposium: The Art of Sight: Where Ophthalmologists Sculpt Vision
- 13:00-14:00; room 8.0 J
- Join Prof. Béatrice Cochener-Lamard, Dr Pavel Stodulka, Dr Alain Saad, Dr Francisco Castro Alonso& Prof.Jose Maria Martinez de la Casa as they discuss their experience with Bausch + Lomb technologies including the OCTAVIUS customized corneal treatment, the Fully Digital SeeLuma™ Visualization Platform, the novel premium LuxLife™ IOL* and the Minimally Invasive Micro Sclerostomy (MIMS®) Glaucoma procedure.
Saturday 7th September
Spotlight on Dry Eye and Ocular Surgery
- 18:00-20:00; Hotel Porta Fira, Barcelona
- Join Prof. Mark Labetoulle, Prof Jesus Merayo-Lloves & Dr Lisa Nijm as they share their clinical experience of dry eye management in ocular surgery. Following the presentations, you will also have the opportunity to view our innovation stand and congress poster portfolio and engage in an open discussion and share best practices.
Sunday 8th September
Lift off: Connect and Create in Ophthalmology!
- 18:30-22:30; La Llota de Mar, Passeig d’Isabel II, 1, Barcelona (buses depart the congress centre at 17:30)
- A visual extravaganza where you can celebrate the artistry of ophthalmology by networking with peers, exchanging groundbreaking ideas, and learning about the latest innovations from Bausch + Lomb.
Monday 9th September
IME Phaco Session
- 9:00-10:15; Room 8.0 J
- Mr. Hatch Mukherjee from the UK will share his hints and tips to mastering common complex cases with the Stellaris Elite™ Vision Enhancement System.
Bausch + Lomb will host product demonstrations at the company booth throughout the congress. Surgeons can register at https://events.bauschsurgical.eu/escrs-2024/.
The company is also a sponsor of the 75th anniversary of the first intraocular lens implantation celebration, as well as iNovation® Day 2024, where Yehia Hashad, Chief Medical Officer and Executive Vice President, R&D, Bausch + Lomb, will be on the “Managing Presbyopia: Keys to Sustainable Category Growth” panel.
*Pending CE Mark
###
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visitwww.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.
Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circ*mstances after the date of this news release or to reflect actual outcomes, unless required by law.
Media Contact:
Caryn Marshall
caryn.marshall@bausch.com
(908) 493-1381
Investor Contact:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)
(908) 927-0735
© 2024 Bausch + Lomb.
TEN.0059.USA.24
